The Promise of Saw Palmetto for Hair Growth in Men & Women
- Cat Paquin
- Oct 3
- 2 min read

Androgenetic alopecia, or pattern baldness, is a common hair loss condition in
both men and women. It affects nearly 80% of men as they age, and, strangely, it
is becoming more common. Emerging research is establishing saw palmetto
berry as a herb that can safely help.
There are only two FDA approved drugs on the market for hair loss: minoxidil
and finasteride. But only about 20% of people who use them get substantial
results. And there are considerable side effects. Minoxidil is a topical treatment
that can cause scalp irritation, allergic contact dermatitis and facial hair in
women. Finasteride can cause erectile dysfunction and loss of libido.
Previous research has suggested that saw palmetto berry works as a hair loss
supplement. Like saw palmetto, finasteride is primarily used in the treatment of
benign prostatic hyperplasia (enlarged prostate).
This new 16 week placebo-controlled, double-blind study gave men and women
with mild-to-moderate androgenetic alopecia either a placebo or 100mg of saw
palmetto berry extract standardized to 85% fatty acids and sterols and 2-3% β-
sitosterol.
The hair comb test revealed that, while hair fall significantly increased in the
placebo group, it significantly decreased by 29% in the saw palmetto group. The
hair pull test found a similar 20.52% reduction in hair fall. 33.3% of people on
saw palmetto experienced improvement in the amount of hair covering the scalp,
and significantly more people in the saw palmetto group positively evaluated their
improvement in hair thickness. 33.33% positively evaluated overall appearance,
amount of hair, and new hair growth.
While hair density continued worsening by 3.23% in the placebo group, it
increased by a significant 5.17% in the saw palmetto group. Hair thickness also
improved significantly in the herb group.
An added advantage over the drugs is that, in this study, the saw palmetto berry
was very safe.
Clin Cosmet Investig Dermatol. 2023;16:3251-3266.








Comments